Gleevec

Type: Product
Name: Gleevec
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Novartis' vaccine sales decline ahead of GSK transfer

Novartis' soon-to-be-divested vaccines business was the only division not to show revenue and earnings growth in the second quarter, while overall sales at the group rose 2 per cent to $14.64bn.The vaccines unit - which will be transferred to GlaxoSmithKline ... [Published PMLive - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 18 2014 - 1 reports

Novartis Misses Estimates as Vaccine Unit Being Sold Slumps

(Updates with analyst comment in fourth paragraph.)July 17 (Bloomberg) -- Novartis AG, the world’s largest drugmaker by revenue, reported second-quarter profit that missed analysts’ estimates, dragged down by declining sales and a worsening loss in the ... [Published Washington Post - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Novartis Q2 results by key product

07:42 ET | About: Novartis AG (NVS)Novartis (NYSE:NVS) Q2 pharmaceutical sales by selected product: Gleevec/Glivec: $1,199M (+0.8%); Diovan/Co-Diovan: $743M (-19.9%); Gilenya: $606M (+29.5%); Sandostatin: $417M (+3.2%); Exforge: $370M (-1.9%); Afinitor/Votubia: ... [Published Seeking Alpha - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Novartis sales boosted by emerging markets and Gilenya

Novartis has posted a solid set financials for the second quarter, with net profit reaching $2.59 billion, up 3%, while group sales edged up 2% to $14.64 billion.Pharmaceutical turnover inched up 1% to $8.20 billion, hit by a 20% fall in sales of the ... [Published Pharma Times - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners

The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall. ... [Published Stockboard Media Inc. - Jul 16 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Cover Story: In Portland, a revolution in targeted treatments

, The Portland Business JournalThere is no question that we can defeat cancer. What it requires is knowledge. When we understand what is broken, we can fix it.”That quote from Brian Druker on Oregon Health & Science University’s Knight Cancer Institute ... [Published Seattle TechFlash - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Pete Julian's race isn't over, but the Oregon Project coach is kicking cancer

The news, when it came in 2008, was direct, brutal and bleak.Pete Julian's third cancer surgery had been only partially successful.There still were at least three gastrointestinal stromal tumors in his body, probably more. The surgeons couldn't get them ... [Published Oregonian - Jul 10 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Access program helps poor cancer patients get treatment

MANILA, Philippines - A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps underprivileged patients get the cancer treatments they need.“For over a decade now, Novartis has helped extend the ... [Published Philippine Star - Jul 10 2014]
First reported Jul 06 2014 - Updated Jul 07 2014 - 1 reports

The end of the US BigPharma’s money spinner?

Many self-styled libertarians have been celebrating the rise of Uber. Their story is that Uber is a dynamic start-up that has managed to disrupt the moribund cab industry.The company now has a market capitalization of US$17 billion.While Uber's market ... [Published Bangla Mirror - Jul 06 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 2 reports

Novartis pulls EMA app for new Tasigna use, but wins new NICE nod for Gleevec

As blood cancer wonder-drug Gleevec ages, Novartis ($NVS) is trying to build out indications for follow-up Tasigna. After an up-and-down week for the pair, the Swiss pharma is now short a potential Tasigna label expansion, thanks to a snag in Europe. ... [Published FiercePharma - Jun 30 2014]
First reported Jun 26 2014 - Updated Jun 27 2014 - 2 reports

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft guidance proposing to recommend Swiss drug major Novartis’ (NOVN: VX) Glivec (imatinib) after surgery for some people with gastro-intestinal stromal ... [Published Pharma Letter - Jun 27 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

[Comment] A modest but meaningful decision for Indian drug patents

On April 1, 2013, the Indian Supreme Court released its long-awaited decision on Novartis AG v Union of India & Others, better known as the Glivec (Gleevec in the USA; imatinib mesylate) patent case. Although neither the resounding victory for access ... [Published The Lancet online - Jun 27 2014]

Quotes

"In case of a suspected interaction, and if pharmacokinetic data are not available, physicians and pharmacists should balance the available evidence, if possible, extrapolate available pharmacokinetic data for an individual patient, and monitor closely for toxic effects and response" they conclude
"Known methods for preparing such pyrimidine derivatives have many synthetic drawbacks such as lacking the ability to regioselectively introduce substituents at the 2-, 4-, or 6-position in high yields. See M Botta , Nucleosides Nucleotides, 13, 8, 1994, 1769-78; M Ban , Bioorg. Med. Chem., 6, 7, 1998, 1057-68; Y Fellahi, Eur. J Med. Chem. Chim. Ther., 31, 1, 1996, 77-82; T J Delia , J Het. Chem., 35, 2, 1998, 269-74; H Uchel, Tetraheron Lett., 36, 52, 1995, 9457-60; and Y Nezu, Pestic. Sci., 47, 2, 1996, 115-24."

More Content

All (130) | News (103) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - 5 hours ago]
Phenotypic Assays in Cancer Drug Discovery [Published In the Pipeline - Jul 24 2014]
VERTEX PHARMACEUTICALS : Patent Issued for Proc... [Published 4 Traders - Jul 24 2014]
Will India’s IP law and policy ‘Modi-fy’? [Published Express Pharma - Jul 22 2014]
A clear policy framework must: Edgard A Olaizola [Published Smart Investor - Jul 20 2014]
Novartis cancer patient access program lauded [Published Philippine Daily Inquirer - Jul 18 2014]
Novartis' vaccine sales decline ahead of GSK tr... [Published PMLive - Jul 18 2014]
Forget Earnings: Catalysts Incoming for Novarti... [Published Motley Fool - Jul 17 2014]
Novartis Q2 results by key product [Published Seeking Alpha - Jul 17 2014]
Novartis sales boosted by emerging markets and ... [Published Pharma Times - Jul 17 2014]
Novartis Misses Estimates as Vaccine Unit Being... [Published Washington Post - Jul 17 2014]
Methods and compositions for modulation of bloo... [Published PharmCast - Jul 17 2014]
Turnaround Stories Lead Reni Benjamin's Biotech... [Published Stockboard Media Inc. - Jul 16 2014]
Cancer care at UCLA earns top rating [Published Examiner.com - Jul 16 2014]
Ariad Stock's Biggest Risk Is Its Only Hope [Published Motley Fool - Jul 15 2014]
The High Cost of Second-Generation TKIs for CML... [Published PR Newswire: General Business - Jul 15 2014]
MannKind: Are These Top Big Pharma Companies Po... [Published Seeking Alpha - Jul 14 2014]
Kinase Inhibitors for Treating Cancer: Industry... [Published MarketResearch.com - Jul 12 2014]
Cover Story: In Portland, a revolution in targe... [Published Seattle TechFlash - Jul 11 2014]
RheumShorts: Fibromyalgia, Scleroderma, Spondyl... [Published MedPageToday.com - medical news plus CME for ph ... - Jul 10 2014]
Gilead Sciences: Cause For Concern? [Published Seeking Alpha - Jul 10 2014]
Pete Julian's race isn't over, but the Oregon P... [Published Oregonian - Jul 10 2014]
Access program helps poor cancer patients get t... [Published Philippine Star - Jul 10 2014]
Sanofi Is Buying Shares Of Regeneron - You Shou... [Published Seeking Alpha - Jul 09 2014]
Top 100 Agencies 2014: Harrison and Star [Published Medical Marketing And Media - Jul 09 2014]
EU approves GSK's Mekinist and Novartis will re... [Published FiercePharma - Jul 07 2014]
The end of the US BigPharma’s money spinner? [Published Bangla Mirror - Jul 06 2014]
The Fight Against Cancer Just Took an Innovativ... [Published Huffington Post Canada - Jul 04 2014]
Patent evergreening in the pharmaceutical industry [Published Biz Community - Jul 04 2014]
"Monohydrate Crystalline Form of 3-(5-(4-(3-Flu... [Published HispanicBusiness.com - Jul 03 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Phenotypic Assays in Cancer Drug Discovery [Published In the Pipeline - Jul 24 2014]
The topic of phenotypic screening has come up around here many times, as indeed it comes up very often in drug discovery. Give your compounds to cells or to animals and look for the effect you want: what could be simpler? Well, a lot of things could, ...
The High Cost of Second-Generation TKIs for CML... [Published PR Newswire: General Business - Jul 15 2014]
BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that, despite the fact that the treatment armamentarium for chronic myeloid leukemia (CML) in Brazil and Mexico includes all three tyrosine kinase inhibitors (TKIs)—Novartis' ...
RheumShorts: Fibromyalgia, Scleroderma, Spondyl... [Published MedPageToday.com - medical news plus CME for ph ... - Jul 10 2014]
(MedPage Today) -- News in rheumatology this week included water therapy for fibromyalgia, Gleevec for the often-lethal interstitial lung disease in scleroderma, and a temporary setback for apremilast in ankylosing spondylitis. ...
[Comment] A modest but meaningful decision for ... [Published The Lancet online - Jun 27 2014]
On April 1, 2013, the Indian Supreme Court released its long-awaited decision on Novartis AG v Union of India & Others, better known as the Glivec (Gleevec in the USA; imatinib mesylate) patent case. Although neither the resounding victory for access ...
This Time It's Personal: Tailoring cancer treat... [Published 3quarksdaily - Jun 19 2014]
Lauren Gravitz in Scientific American: Every cancer has a weak spot — a genetic vulnerability that could be exploited by the right drug — and many envision a day when the genome of every cancer will be sequenced, in full or in part, and then paired ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.